Overview

On 6 November 2026, at the Golden Panda Global Innovation and Entrepreneurship Competition, LivingPHOENIX Regenerative Technology Development (Chengdu) Co., Ltd. announced that its independently developed Sterile Biomimetic Collagen Dressing had been granted a medical device registration certificate by the Sichuan Medical Products Administration. This marks the first‑ever certificate in China for a triple‑helix biomimetic collagen medical device, signalling a shift from “catching up” to “leading” in high‑end regenerative‑medicine materials.

Regulatory Approval

The certificate, issued by the Sichuan Medical Products Administration, classifies the dressing as a Class II medical device and confirms that the product can withstand terminal wet‑heat sterilisation at 121 °C while retaining its native triple‑helix structure. LivingPHOENIX plans to certify seven additional products—including liquid dressings, repair dressings, scar gels and gynecological gels—by December 2026, creating a portfolio of eight medical‑grade dressings.

Patent Grants

Within the same week, the China National Intellectual Property Administration (CNIPA) granted two core invention patents via its green‑channel pre‑examination:

  • Patent 1: “A Triple‑Helix Biomimetic Collagen Self‑Crosslinking Hydrogel, Extracellular Matrix Based on Wet Heat Sterilisation Process, Preparation Method, and Use” (granted in 37 working days).
  • Patent 2: “A Similar Material Patent Based on Radiation Sterilisation Process” (granted in 39 working days).

These patents are described as the world’s only core patents for third‑generation triple‑helix biomimetic collagen hydrogels that resolve the historic “sterilisation vs. structure retention” conflict.

Competition Achievement

LivingPHOENIX competed against 2,119 innovative projects from countries including South Korea, the United States, Germany and China, spanning sectors such as AI, electronic information, pharmaceuticals & health, new materials, new energy and advanced manufacturing. The company secured the Third Prize at the 2026 Golden Panda Competition, underscoring the commercial and technological relevance of its breakthrough.

Technology Overview

The company’s third‑generation Triple‑Helix Biomimetic Collagen‑Based ECM platform combines:

  • Green biomanufacturing of amino acids (proline, hydroxyproline) from renewable biomass substrates like corn starch and glucose via microbial fermentation.
  • Aqueous‑phase chemical polycondensation that precisely replicates the homologous triple‑helix skeleton of natural collagen.
  • Self‑crosslinking hydrogel technology that requires no exogenous crosslinkers and remains stable under both wet‑heat and radiation sterilisation.

This approach overcomes the limitations of first‑generation animal‑derived collagen (viral risk, immunogenicity) and second‑generation recombinant collagen (incomplete triple‑helix formation).

Product Portfolio & Market Validation

  • Class II Dressing: The newly certified sterile dressing is the flagship product.
  • Functional Cosmetics: The brand SMARTENDER® launched at the 2025 Import Expo, backed by safety and efficacy data from 25,000 cases and praised at the 19th Europe‑China Business and Technology Cooperation Fair.
  • Class III Implants & Aesthetic Devices: Pre‑clinical data from Peking University Third Hospital show superior collagen deposition and regeneration compared with existing animal‑derived and recombinant products.
  • Future Frontier Applications: The company is exploring acellular scaffolds for brain‑computer interfaces (BCI) and tissue engineering, emphasizing “zero animal source, zero fermentation residue, zero exogenous crosslinker.” Joint applications with universities have been submitted to the National Natural Science Foundation of China’s 2026 Major Research Plan for diabetic wound repair.

Investment & Production Plans

LivingPHOENIX intends to invest tens of millions of yuan to build dedicated production bases for Class III device registration and commercialisation, targeting gynecological implants, filler injections and other high‑value consumables.

Intellectual Property Landscape

To date, the company has filed 8 Chinese invention patents (6 granted) and 6 PCT international patents. CNIPA examiners visited the firm on 12 October and 8 June for technical practice, confirming the novelty of the inventions.

Market Outlook

LeadLeo Research estimates the biomimetic collagen sector’s compound annual growth rate (CAGR) at 484 %, projecting the Chinese market size to reach ¥6.778 billion by 2030. Competitors such as Allergan have abandoned recombinant collagen routes, while firms like Stuart Corp are licensing biomimetic synthetic collagen, indicating a rapid industry shift toward structurally authentic collagen.

Awards & Recognition

LivingPHOENIX has received multiple accolades, including:

  • Top 10 Pharma Health in Maker China
  • Champion in Startup Group and Runner‑up in Growth Group at the Sichuan Finals of the China Innovation and Entrepreneurship Competition
  • Third Prize at the Golden Panda Innovation Competition
  • Advancement to national semi‑finals of the Biomanufacturing Competition and Top 10 finals of the Golden Panda High‑Value Patent Cultivation Competition.

Conclusion

The simultaneous achievement of a historic regulatory certificate, rapid patent authorisation, and global competition recognition positions LivingPHOENIX as a pioneer of the “Biomimetic Era” in collagen‑based regenerative medicine, with a clear roadmap toward commercialising Class II and Class III devices, expanding into cosmetics, and exploring frontier BCI applications.